Merck to buy drug developer Immune Design for $300 million
Merck will pay $5.85 in cash for each share of Immune Design. Shares of Immune Design closed at $1.42 on Wednesday.
U.S: Merck & Co Inc said on Thursday it would buy drug developer Immune Design Corp for nearly $300 million, to gain access to its immunotherapy programs.
Merck will pay $5.85 in cash for each share of Immune Design. Shares of Immune Design closed at $1.42 on Wednesday.
Immune Design's treatments help activate the immune system to produce or expand specific immune cells to fight cancer and other diseases.
Read Also: Merck, Pfizer combo treatment improves kidney cancer survival
Seattle, Washington-based Immune Design's pipeline includes late-stage immunotherapy technologies such as Glass And Zvex.
Credit Suisse is the financial adviser to Merck, while Gibson, Dunn & Crutcher LLP its legal adviser.
Lazard is the financial adviser to Immune Design and Cooley LLP the legal counsel.
Read Also: Merck increases price of five drugs including Keytruda in November
The transaction is expected to close early in the second quarter of 2019, the companies said.
Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd